Evidence map›Paper›PMID 40607332›Full record

ReviewRegenerative therapy2025

Detailed revisions to the subordinate regulation following the amendment of the Act on the Safety of Regenerative Medicine in Japan.

Satoshi Hosoya, Yuichiro Ukon, Kazuki Morita, Eisuke Minegishi, Jun Sugihara, Manabu Hasegawa

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Satoshi HosoyaResearch and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare, 1-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-8916, Japan.
Yuichiro UkonResearch and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare, 1-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-8916, Japan.
Kazuki MoritaResearch and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare, 1-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-8916, Japan.
Eisuke MinegishiResearch and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare, 1-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-8916, Japan.
Jun SugiharaResearch and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare, 1-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-8916, Japan.
Manabu HasegawaResearch and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare, 1-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-8916, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The amended Act on the Safety of Regenerative Medicine (RM Act) in Japan expands its scope to include

Indexed as

Cabinet orderIn vivo gene therapyMinisterial ordinanceRegenerative medicineThe act on the safety of regenerative medicine

Identifiers

PMID40607332
PMCPMC12221229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.